Daily Stock Analysis, ALKS, Alkermes Plc, priceseries

Alkermes Plc. Daily Stock Analysis
Stock Information
Open
23.64
Close
25.56
High
25.64
Low
23.64
Previous Close
24.00
Daily Price Gain
1.56
YTD High
26.00
YTD High Date
Jan 19, 2022
YTD Low
22.93
YTD Low Date
Jan 5, 2022
YTD Price Change
1.41
YTD Gain
5.84%
52 Week High
33.00
52 Week High Date
Oct 7, 2021
52 Week Low
18.02
52 Week Low Date
Mar 5, 2021
52 Week Price Change
2.69
52 Week Gain
11.76%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 4. 2019
30.00
Jan 23. 2019
32.21
12 Trading Days
7.37%
Link
LONG
Jun 18. 2020
17.75
Jul 13. 2020
19.27
16 Trading Days
8.57%
Link
LONG
Apr 14. 2021
19.23
May 10. 2021
21.83
18 Trading Days
13.50%
Link
LONG
May 26. 2021
22.31
Jun 18. 2021
24.49
16 Trading Days
9.75%
Link
LONG
Jul 30. 2021
25.87
Aug 16. 2021
28.15
11 Trading Days
8.83%
Link
Company Information
Stock Symbol
ALKS
Exchange
NasdaqGS
Company URL
http://www.alkermes.com
Company Phone
00-353-1-772-8000
CEO
Richard F. Pops
Headquarters
-
Business Address
CONNAUGHT HOUSE, 1 BURLINGTON ROAD, DUBLIN 4, IRELAND 00000
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Delivery
CIK
0001520262
About

Alkermes Plc is a biopharmaceutical company. It engages in the development, manufacturing and distribution of medicines. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.

Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company's marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.